SCHEDULE 13G/A: AIGH Capital Management and Orin Hirschman Disclose Significant Passive Stake in SCPHARMACEUTICALS INC.

AIGH Capital Management LLC and Orin Hirschman have jointly disclosed beneficial ownership of 8.4% and 8.3% respectively, of SCPHARMACEUTICALS INC.'s common stock as of December 31, 2024, held for ordinary course investment purposes.

Summary

• Orin Hirschman, an individual, and AIGH Capital Management LLC, a Delaware limited liability company, have jointly filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in SCPHARMACEUTICALS INC.
• As of December 31, 2024, Orin Hirschman beneficially owns 4,200,577 shares of SCPHARMACEUTICALS INC. Common Stock, representing 8.4% of the class.
• As of December 31, 2024, AIGH Capital Management LLC beneficially owns 4,174,367 shares of SCPHARMACEUTICALS INC. Common Stock, representing 8.3% of the class.
• Both reporting persons hold sole voting and sole dispositive power over their respective reported shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of ownership, indicating a neutral sentiment. It neither presents overwhelmingly positive nor negative news, but rather a standard regulatory update on a significant stake.

Positives

• The disclosure indicates significant institutional and individual investor confidence in SCPHARMACEUTICALS INC. through substantial ownership stakes.
• The filing explicitly states that the shares are held in the ordinary course of business and not for the purpose of influencing control, suggesting a passive, long-term investment approach by the reporting persons.

Risks

• While the filing states a passive investment intent, a large ownership stake by a single entity or group could still potentially influence future corporate actions or governance, even if not explicitly intended for control.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding the issuer's future performance or strategic direction.

Industry Context

This filing reflects a significant ownership position by an investment firm and its principal in SCPHARMACEUTICALS INC., a common occurrence in the public markets where institutional investors take substantial stakes in companies they believe offer value. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The disclosure of a significant, passive institutional stake may be viewed positively, suggesting a vote of confidence from sophisticated investors, potentially stabilizing the stock or attracting further investment interest.
• Management: Awareness of a large, passive shareholder group may influence management's strategic decisions, though the filing explicitly states no intent to influence control.

Key Dates

Keywords

SCPHARMACEUTICALS INC., Common Stock, Schedule 13G, Beneficial Ownership, Orin Hirschman, AIGH Capital Management LLC, Institutional Investor, Passive Investment, SEC Filing, Equity Stake